NASDAQ:MRNS - Marinus Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.57 +0.34 (+6.50 %)
(As of 05/24/2018 12:07 PM ET)
Previous Close$5.69
Today's Range$5.54 - $6.17
52-Week Range$1.13 - $9.87
Volume53,086 shs
Average Volume368,641 shs
Market Capitalization$199.36 million
P/E RatioN/A
Dividend YieldN/A
Beta2.6

About Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals logoMarinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRNS
CUSIPN/A
Phone484-801-4670

Debt

Debt-to-Equity RatioN/A
Current Ratio30.01
Quick Ratio30.01

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.31 per share
Price / Book4.25

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-18,890,000.00
Net MarginsN/A
Return on Equity-41.07%
Return on Assets-38.45%

Miscellaneous

Employees16
Outstanding Shares40,520,000

Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. View Marinus Pharmaceuticals' Earnings History.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Marinus Pharmaceuticals.

What price target have analysts set for MRNS?

5 brokerages have issued twelve-month target prices for Marinus Pharmaceuticals' stock. Their forecasts range from $11.00 to $33.00. On average, they expect Marinus Pharmaceuticals' stock price to reach $18.00 in the next twelve months. View Analyst Ratings for Marinus Pharmaceuticals.

Who are some of Marinus Pharmaceuticals' key competitors?

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the folowing people:
  • Mr. Christopher Michael Cashman, Exec. Chairman, Chief Exec. Officer and Pres (Age 61)
  • Mr. Edward F. Smith, CFO, VP, Treasurer & Sec. (Age 47)
  • Dr. Lorianne K. Masuoka M.D., Chief Medical Officer (Age 57)
  • Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations
  • Dr. Kimberly A. McCormick PharmD, Head of Regulatory Affairs

Has Marinus Pharmaceuticals been receiving favorable news coverage?

Media stories about MRNS stock have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Marinus Pharmaceuticals earned a media sentiment score of 0.23 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 45.29 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (4.12%), BlackRock Inc. (1.57%), Millennium Management LLC (1.43%), Artal Group S.A. (1.23%), JPMorgan Chase & Co. (0.24%) and Barclays PLC (0.15%). Company insiders that own Marinus Pharmaceuticals stock include Anand Mehra, Bain Capital Life Sciences Inv, Christopher Michael Cashman, Edward F Smith and Vii Lp Canaan. View Institutional Ownership Trends for Marinus Pharmaceuticals.

Which major investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, A.R.T. Advisors LLC and BlackRock Inc.. Company insiders that have sold Marinus Pharmaceuticals company stock in the last year include Bain Capital Life Sciences Inv, Christopher Michael Cashman and Edward F Smith. View Insider Buying and Selling for Marinus Pharmaceuticals.

Which major investors are buying Marinus Pharmaceuticals stock?

MRNS stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., JPMorgan Chase & Co. and Barclays PLC. View Insider Buying and Selling for Marinus Pharmaceuticals.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $5.55.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $199.36 million. Marinus Pharmaceuticals employs 16 workers across the globe.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 170 N. Radnor Chester Rd Suite 250, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]


MarketBeat Community Rating for Marinus Pharmaceuticals (MRNS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  327
MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote "Outperform" if you believe MRNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Marinus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $18.00, suggesting that the stock has a possible upside of 223.16%. The high price target for MRNS is $33.00 and the low price target for MRNS is $11.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.00$18.75$20.6667$11.00
Price Target Upside: 223.16% upside275.00% upside239.91% upside165.06% upside

Marinus Pharmaceuticals (NASDAQ:MRNS) Consensus Price Target History

Price Target History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ:MRNS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018Robert W. BairdInitiated CoverageOutperform$15.00HighView Rating Details
4/19/2018MizuhoReiterated RatingBuy$13.00LowView Rating Details
2/15/2018HC WainwrightInitiated CoverageBuy ➝ Buy$33.00HighView Rating Details
12/14/2017LaidlawInitiated CoverageBuy ➝ Buy$18.00HighView Rating Details
9/12/2017JMP SecuritiesReiterated RatingOutperform$5.00 ➝ $11.00HighView Rating Details
10/3/2016Jefferies GroupReiterated RatingBuy$3.00N/AView Rating Details
6/28/2016Stifel NicolausReiterated RatingHoldN/AView Rating Details
6/14/2016Goldman Sachs GroupDowngradeBuy ➝ NeutralN/AView Rating Details
6/14/2016OppenheimerDowngradeOutperform ➝ Market PerformN/AView Rating Details
6/14/2016Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$14.00 ➝ $2.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Marinus Pharmaceuticals (NASDAQ:MRNS) Earnings History and Estimates Chart

Earnings by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ MRNS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018($0.16)N/AView Earnings Details
5/2/2018Q1 2018($0.16)($0.15)ViewN/AView Earnings Details
3/6/2018Q4 2017($0.13)($0.20)ViewN/AView Earnings Details
10/31/2017Q3 2017($0.17)($0.15)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.27)($0.21)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.32)($0.26)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.33)($0.31)ViewN/AView Earnings Details
11/3/2016Q3($0.43)($0.33)ViewN/AView Earnings Details
8/9/2016Q2($0.38)($0.46)ViewN/AView Earnings Details
5/2/2016Q1 2016($0.41)($0.37)ViewN/AView Earnings Details
3/7/2016Q416($0.38)($0.45)ViewN/AView Earnings Details
10/29/2015Q3 2015($0.51)($0.35)ViewN/AView Earnings Details
8/4/2015Q2 2015($0.51)($0.37)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.47)($0.50)ViewN/AView Earnings Details
3/12/2015Q4 2014($0.26)ViewN/AView Earnings Details
11/13/2014Q3 14($0.50)($0.30)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Marinus Pharmaceuticals (NASDAQ:MRNS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Marinus Pharmaceuticals (NASDAQ MRNS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 55.21%
Insider Trading History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Institutional Ownership by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ MRNS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/29/2018Edward F SmithCFOSell3,000$7.91$23,730.0049,800View SEC Filing  
1/18/2018Christopher Michael CashmanCEOSell9,566$6.28$60,074.48247,903View SEC Filing  
12/19/2017Bain Capital Life Sciences InvMajor ShareholderSell1,272,547$7.88$10,027,670.36View SEC Filing  
12/15/2017Bain Capital Life Sciences InvMajor ShareholderSell822,547$8.10$6,662,630.70View SEC Filing  
10/20/2016Anand MehraMajor ShareholderSell750,683$1.39$1,043,449.37View SEC Filing  
8/8/2016Vii Lp CanaanMajor ShareholderSell149,154$1.50$223,731.00View SEC Filing  
8/4/2016Vii Lp CanaanMajor ShareholderSell145,583$1.50$218,374.50View SEC Filing  
7/29/2016Vii Lp CanaanMajor ShareholderSell24,540$1.71$41,963.40View SEC Filing  
7/27/2016Vii Lp CanaanMajor ShareholderSell20,589$1.81$37,266.09View SEC Filing  
7/26/2016Vii Lp CanaanMajor ShareholderSell20,380$1.81$36,887.80View SEC Filing  
7/25/2016Vii Lp CanaanMajor ShareholderSell270,750$1.90$514,425.00View SEC Filing  
4/21/2015Gail M FarfelInsiderSell30,000$9.48$284,400.00View SEC Filing  
8/5/2014Domain Partners Vi, L.P.Major ShareholderBuy419,744$8.00$3,357,952.00View SEC Filing  
8/5/2014Stephen M BlochDirectorBuy625,000$8.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Marinus Pharmaceuticals (NASDAQ MRNS) News Headlines

Source:
DateHeadline
Marinus +8.8% with Baird bullish on blockbuster drug potentialMarinus +8.8% with Baird bullish on 'blockbuster' drug potential
seekingalpha.com - May 24 at 8:28 AM
Marinus Pharmaceuticals (MRNS) Coverage Initiated at Robert W. BairdMarinus Pharmaceuticals (MRNS) Coverage Initiated at Robert W. Baird
www.americanbankingnews.com - May 23 at 4:52 PM
Marinus Pharmaceuticals to Present at the UBS Global Healthcare ConferenceMarinus Pharmaceuticals to Present at the UBS Global Healthcare Conference
finance.yahoo.com - May 14 at 8:41 AM
Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals — Fundamental Analysis, Key Performance IndicationsConsolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals — Fundamental Analysis, Key Performance Indications
finance.yahoo.com - May 11 at 8:42 AM
Marinus Pharmaceuticals, Inc. (MRNS) Receives Consensus Recommendation of "Buy" from AnalystsMarinus Pharmaceuticals, Inc. (MRNS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 8 at 3:18 AM
Marinus Pharmaceuticals (MRNS) Announces  Earnings ResultsMarinus Pharmaceuticals (MRNS) Announces Earnings Results
www.americanbankingnews.com - May 3 at 7:29 PM
Marinus Pharmaceuticals (MRNS) Stock Rating Upgraded by ValuEngineMarinus Pharmaceuticals (MRNS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 11:38 PM
Marinus Pharmaceuticals: 1Q Earnings SnapshotMarinus Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 5:28 PM
Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial ResultsMarinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results
finance.yahoo.com - May 2 at 8:30 AM
Marinus Pharmaceuticals (MRNS) Scheduled to Post Quarterly Earnings on MondayMarinus Pharmaceuticals (MRNS) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 23 at 8:08 AM
Marinus Pharmaceuticals (MRNS) Receives Buy Rating from MizuhoMarinus Pharmaceuticals (MRNS) Receives Buy Rating from Mizuho
www.americanbankingnews.com - April 19 at 6:50 AM
Marinus Pharmaceuticals (MRNS) Rating Increased to Sell at ValuEngineMarinus Pharmaceuticals (MRNS) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - April 15 at 11:43 PM
Marinus Pharmaceuticals, Inc. (MRNS) Receives Average Recommendation of "Buy" from BrokeragesMarinus Pharmaceuticals, Inc. (MRNS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 13 at 3:29 AM
Marinus Pharmaceuticals (MRNS) Upgraded by ValuEngine to HoldMarinus Pharmaceuticals (MRNS) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 10 at 7:51 PM
Marinus Pharmaceuticals (MRNS) Downgraded to Hold at BidaskClubMarinus Pharmaceuticals (MRNS) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - March 30 at 2:19 PM
Mid-Day Market Update: Crude Oil Up 2.5%; Arena Pharmaceuticals Shares Spike Higher - NasdaqMid-Day Market Update: Crude Oil Up 2.5%; Arena Pharmaceuticals Shares Spike Higher - Nasdaq
www.nasdaq.com - March 20 at 5:09 PM
Mid-Afternoon Market Update: MuleSoft Gains Following Report Of Takeover Interest From Salesforce; Proteostasis ... - NasdaqMid-Afternoon Market Update: MuleSoft Gains Following Report Of Takeover Interest From Salesforce; Proteostasis ... - Nasdaq
www.nasdaq.com - March 20 at 5:09 PM
Marinus Pharmaceuticals Inc (MRNS) Receives Consensus Rating of "Buy" from AnalystsMarinus Pharmaceuticals Inc (MRNS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 19 at 5:32 PM
Mizuho Begins Coverage on Marinus Pharmaceuticals (MRNS)Mizuho Begins Coverage on Marinus Pharmaceuticals (MRNS)
www.americanbankingnews.com - March 19 at 5:02 PM
Marinus Pharmaceuticals to Present at the Barclays Global Healthcare ConferenceMarinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference
finance.yahoo.com - March 8 at 8:33 AM
Marinus Pharmaceuticals (MRNS) Announces Quarterly  Earnings ResultsMarinus Pharmaceuticals (MRNS) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 7 at 11:50 AM
Mid-Day Market Update: Dow Falls Over 100 Points; Amedica Shares Spike HigherMid-Day Market Update: Dow Falls Over 100 Points; Amedica Shares Spike Higher
www.benzinga.com - March 6 at 5:33 PM
Heres Why Marinus Pharmaceuticals Dropped as Much as 17.7% TodayHere's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today
www.msn.com - March 6 at 5:33 PM
Marinus Pharma shares slide 14% premarket after company posts wider-than-expected loss - MarketWatchMarinus Pharma shares slide 14% premarket after company posts wider-than-expected loss - MarketWatch
www.marketwatch.com - March 6 at 8:25 AM
Marinus Pharmaceuticals - Be Greedy When Others Are Fearful ... - Seeking AlphaMarinus Pharmaceuticals - Be Greedy When Others Are Fearful ... - Seeking Alpha
seekingalpha.com - March 6 at 8:25 AM
Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results - GlobeNewswire (press release)Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:25 AM
Marinus Pharmaceuticals Provides Business Update and 2017 Financial ResultsMarinus Pharmaceuticals Provides Business Update and 2017 Financial Results
finance.yahoo.com - March 6 at 8:25 AM
Marinus Pharma shares slide 14% premarket after company posts wider-than-expected lossMarinus Pharma shares slide 14% premarket after company posts wider-than-expected loss
finance.yahoo.com - March 6 at 8:25 AM
Comparing Histogenics (HSGX) & Marinus Pharmaceuticals (MRNS)Comparing Histogenics (HSGX) & Marinus Pharmaceuticals (MRNS)
www.americanbankingnews.com - March 6 at 3:10 AM
Marinus Pharmaceuticals (MRNS) to Release Quarterly Earnings on MondayMarinus Pharmaceuticals (MRNS) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - March 5 at 2:34 AM
Marinus Pharmaceuticals Inc (MRNS) Shares Bought by EAM Investors LLCMarinus Pharmaceuticals Inc (MRNS) Shares Bought by EAM Investors LLC
www.americanbankingnews.com - March 1 at 12:04 PM
Ascend Capital LLC Purchases Shares of 1,012,854 Marinus Pharmaceuticals Inc (MRNS)Ascend Capital LLC Purchases Shares of 1,012,854 Marinus Pharmaceuticals Inc (MRNS)
www.americanbankingnews.com - March 1 at 4:40 AM
Is There Now An Opportunity In Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?Is There Now An Opportunity In Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?
finance.yahoo.com - February 23 at 5:48 PM
Marinus Pharmaceuticals (MRNS) Coverage Initiated at HC WainwrightMarinus Pharmaceuticals (MRNS) Coverage Initiated at HC Wainwright
www.americanbankingnews.com - February 15 at 9:10 PM
Marinus Pharmaceuticals Inc (MRNS) CFO Edward F. Smith Sells 3,000 SharesMarinus Pharmaceuticals Inc (MRNS) CFO Edward F. Smith Sells 3,000 Shares
www.americanbankingnews.com - January 29 at 9:14 PM
Marinus Pharmaceuticals Sees Unusually Large Options Volume (MRNS)Marinus Pharmaceuticals Sees Unusually Large Options Volume (MRNS)
www.americanbankingnews.com - January 26 at 2:22 AM
Marinus Pharmaceuticals Target of Unusually Large Options Trading (MRNS)Marinus Pharmaceuticals Target of Unusually Large Options Trading (MRNS)
www.americanbankingnews.com - January 26 at 2:22 AM
Christopher Michael Cashman Sells 9,566 Shares of Marinus Pharmaceuticals Inc (MRNS) StockChristopher Michael Cashman Sells 9,566 Shares of Marinus Pharmaceuticals Inc (MRNS) Stock
www.americanbankingnews.com - January 22 at 9:22 PM
3 Best Healthcare Stocks of 20173 Best Healthcare Stocks of 2017
finance.yahoo.com - January 3 at 9:15 AM
Marinus Pharmaceuticals (MRNS) Upgraded to Buy by BidaskClubMarinus Pharmaceuticals (MRNS) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - December 30 at 2:08 PM
Make Or Break Year Awaits VTVT, Its Advantage MRUS Now, INSY Marches OnMake Or Break Year Awaits VTVT, It's Advantage MRUS Now, INSY Marches On
www.nasdaq.com - December 29 at 10:23 AM
Key Risks Facing Marinus Pharmaceuticals in December 2017Key Risks Facing Marinus Pharmaceuticals in December 2017
finance.yahoo.com - December 28 at 10:35 AM
Why Ganaxalone Is a Promising Drug CandidateWhy Ganaxalone Is a Promising Drug Candidate
finance.yahoo.com - December 27 at 5:51 PM
What Analysts Recommend for Marinus Pharmaceuticals in DecemberWhat Analysts Recommend for Marinus Pharmaceuticals in December
finance.yahoo.com - December 27 at 5:51 PM
Teligent (TLGT) & Marinus Pharmaceuticals (MRNS) Financial AnalysisTeligent (TLGT) & Marinus Pharmaceuticals (MRNS) Financial Analysis
www.americanbankingnews.com - December 26 at 3:46 AM
Marinus Pharmaceuticals Inc (MRNS) Major Shareholder Bain Capital Life Sciences Inv Sells 1,272,547 SharesMarinus Pharmaceuticals Inc (MRNS) Major Shareholder Bain Capital Life Sciences Inv Sells 1,272,547 Shares
www.americanbankingnews.com - December 19 at 11:32 PM
Marinus Pharmaceuticals Inc (MRNS) Major Shareholder Sells $6,662,630.70 in StockMarinus Pharmaceuticals Inc (MRNS) Major Shareholder Sells $6,662,630.70 in Stock
www.americanbankingnews.com - December 19 at 11:32 PM
Why Mattel, Marinus Pharmaceuticals, and Northern Dynasty Minerals Slumped Today - Motley FoolWhy Mattel, Marinus Pharmaceuticals, and Northern Dynasty Minerals Slumped Today - Motley Fool
www.fool.com - December 19 at 9:56 AM
Why Mattel, Marinus Pharmaceuticals, and Northern Dynasty Minerals Slumped TodayWhy Mattel, Marinus Pharmaceuticals, and Northern Dynasty Minerals Slumped Today
finance.yahoo.com - December 18 at 4:57 PM
Heres Why Marinus Pharmaceuticals Is Soaring Today - Motley FoolHere's Why Marinus Pharmaceuticals Is Soaring Today - Motley Fool
www.fool.com - December 16 at 4:55 PM

SEC Filings

Marinus Pharmaceuticals (NASDAQ:MRNS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Marinus Pharmaceuticals (NASDAQ:MRNS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Marinus Pharmaceuticals (NASDAQ MRNS) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.